These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 17891370)
41. Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma. Müller-Horvat C; Radny P; Eigentler TK; Schäfer J; Pfannenberg C; Horger M; Khorchidi S; Nägele T; Garbe C; Claussen CD; Schlemmer HP Eur J Cancer; 2006 Feb; 42(3):342-50. PubMed ID: 16364631 [TBL] [Abstract][Full Text] [Related]
42. Elective full-body screening examinations: a plea for MRI. Goyen M; Debatin JF World Hosp Health Serv; 2005; 41(2):32-4, 40, 42. PubMed ID: 16104457 [TBL] [Abstract][Full Text] [Related]
43. [Teleradiology: economic research analysis of CT investigations in a small hospital]. Plathow C; Walz M; Essig M; Engelmann U; Schulz-Ertner D; Delorme S; Kauczor HU Rofo; 2005 Jul; 177(7):1016-26. PubMed ID: 15973605 [TBL] [Abstract][Full Text] [Related]
44. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Ghanem N; Uhl M; Brink I; Schäfer O; Kelly T; Moser E; Langer M Eur J Radiol; 2005 Jul; 55(1):41-55. PubMed ID: 15950100 [TBL] [Abstract][Full Text] [Related]
45. Whole-body MR imaging of bone marrow. Schmidt GP; Schoenberg SO; Reiser MF; Baur-Melnyk A Eur J Radiol; 2005 Jul; 55(1):33-40. PubMed ID: 15950099 [TBL] [Abstract][Full Text] [Related]
46. Whole-body MR angiography using a novel 32-receiving-channel MR system with surface coil technology: first clinical experience. Fenchel M; Requardt M; Tomaschko K; Kramer U; Stauder NI; Naegele T; Schlemmer HP; Claussen CD; Miller S J Magn Reson Imaging; 2005 May; 21(5):596-603. PubMed ID: 15834920 [TBL] [Abstract][Full Text] [Related]
47. Diagnostic imaging costs: are they driving up the costs of hospital care? Beinfeld MT; Gazelle GS Radiology; 2005 Jun; 235(3):934-9. PubMed ID: 15833988 [TBL] [Abstract][Full Text] [Related]
56. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management. Pfannenberg AC; Oechsle K; Bokemeyer C; Kollmannsberger C; Dohmen BM; Bares R; Hartmann JT; Vonthein R; Claussen CD World J Urol; 2004 Jun; 22(2):132-9. PubMed ID: 14735310 [TBL] [Abstract][Full Text] [Related]
57. [Tumor staging with PET/CT. Detection of a second tumor]. Gutzeit A; Debatin JF; Antoch G Rofo; 2004 Jan; 176(1):122-4. PubMed ID: 14712416 [No Abstract] [Full Text] [Related]